Skip to main content
Rapid Dose Therapeutics Corp logo

Rapid Dose Therapeutics Corp — Investor Relations & Filings

Ticker · DOSE ISIN · CA75339A1012 CSE Manufacturing
Open in API
Filings indexed 490 across all filing types
Latest filing 2024-11-01 Regulatory Filings
Country CA Canada
Listing CSE DOSE

About Rapid Dose Therapeutics Corp

https://rapid-dose.com/

Rapid Dose Therapeutics Corp. is a pharma-technology company specializing in proprietary drug delivery technologies engineered to enhance patient outcomes and quality of life. The core business revolves around an innovative oral delivery platform utilizing sublingual thin film strip technology. The company's flagship product, QuickStrip™, is a fast-dissolving system designed for the rapid release of pharmaceuticals, micronized oils, and over-the-counter medicines. QuickStrip™ is distinguished by its ability to achieve blood concentrations comparable to intravenous injection, offering superior bioavailability and rapid onset. RDT provides product innovation, production, and consultation services to the pharmaceutical and healthcare manufacturing sectors for both prescription and non-prescription applications.

Recent filings

Filing Released Lang Actions
Report of Distributions outside Canada (Form 72-503F).pdf
Regulatory Filings Classification · 100% confidence The document is titled 'FORM 72-503F REPORT OF DISTRIBUTIONS OUTSIDE CANADA' and contains detailed information about securities distributed, including CUSIP numbers, number of securities, prices, distribution dates, and dealer/underwriter information. It also includes a certification section by an officer of the issuer. This form is a regulatory filing related to exempt distributions of securities, which is a compliance report rather than a financial report or earnings release. It does not contain financial statements, management discussion, or earnings highlights. The document is a regulatory compliance report filed with securities authorities regarding distributions of securities under exemptions. Therefore, it fits best under Regulatory Filings (RNS).
2024-11-01 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 100% confidence The document is titled 'Form 45-106F1 Report of Exempt Distribution' and contains detailed information about securities distribution, including issuer details, underwriter information, distribution dates, purchaser information, types of securities distributed, compensation related to the distribution, and directors/executive officers information. The form is a regulatory filing used in Canada to report exempt distributions of securities, which is a compliance and disclosure document rather than a financial report or earnings release. It does not contain financial statements, management discussion, or audit information. The document is lengthy (15,000 characters) and is a formal regulatory report. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory compliance documents that do not fit other specific categories.
2024-11-01 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109F2 Certification of Interim Filings by the CEO of Precision Drilling Corporation. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended September 30, 2024. The document is primarily an officer certification letter confirming the accuracy and completeness of the interim filings, referencing National Instrument 52-109. It does not contain the actual interim financial statements or substantive financial data itself, but rather attests to their correctness. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR) itself. The document length is 3410 characters, which is relatively short and consistent with a certification letter rather than a full interim report. Therefore, the correct classification is Regulatory Filings (RNS).
2024-10-30 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a FORM 52-109FV2 Certification of Interim Filings by the CFO of Rapid Dose Therapeutics Corp. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ending August 31, 2024. The text is primarily a certification letter without actual financial data or detailed financial statements. According to the CERTIFICATION RULE, such officer certifications referencing interim filings should be classified as Regulatory Filings (RNS), not as the interim report itself (IR). The document length is under 5,000 characters and contains no substantive financial data, confirming it is a certification rather than the report itself.
2024-10-30 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification statement by the CEO regarding the review and fair presentation of the interim financial report and interim MD&A for the period ending August 31, 2024. It is a Form 52-109FV2 certification, which is a regulatory attestation related to interim filings for a venture issuer. The document does not contain actual financial data or substantive financial analysis but serves as a certification of the interim filings. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is short (2993 characters), and it is clearly a certification letter, not the interim report or MD&A itself.
2024-10-30 English
Interim MD&A - English.pdf
Management Reports Classification · 100% confidence The document is titled 'Management’s Discussion and Analysis August 31, 2024' and contains detailed discussion and analysis of the company's financial condition and results of operations for the three-month period ended August 31, 2024. It includes financial figures, business overview, forward-looking statements, and operational details. The presence of substantive financial data and management commentary indicates this is a Management Discussion and Analysis report. The document length is 15,000 characters, which is substantial and contains actual financial data, not just an announcement or certification. Therefore, it fits the category of Management Reports (MDA).
2024-10-30 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.